Quantcast

Latest Ampio Pharmaceuticals Inc. Stories

2014-02-27 20:23:05

GREENWOOD VILLAGE, Colo., Feb. 27, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has priced an underwritten public offering of 8,500,000 shares of its common stock. The shares will be sold at a price to the public of $7.00 per share for gross proceeds of $59.5 million. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the...

2014-02-24 08:27:32

GREENWOOD VILLAGE, Colo., Feb. 24, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it intends to offer 8,000,000 shares of its common stock in a proposed underwritten public offering. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Ampio expects to grant the underwriters a 30-day option to purchase additional shares of...

2014-02-18 08:31:01

GREENWOOD VILLAGE, Colo., Feb. 18, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it has completed enrollment and dosing of 500 patient in the pivotal trial of Ampion((TM)) for the treatment of acute osteoarthritis of-the-knee (OAK). http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1 (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained: "This phase III,...

2014-02-13 08:29:59

GREENWOOD VILLAGE, Colo., Feb. 13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced preliminary biochemical analysis of samples of synovial fluid drawn from the index knee (treated knee) of a subset of patients who participated in the SPRING study. This synovial analysis, suggested by the FDA, tests the change in expression of signaling and structural proteins that arise from the treatment of the knee with either Ampion(TM) or the saline vehicle...

2014-02-04 08:28:44

GREENWOOD VILLAGE, Colo., Feb. 4, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio" or the "Company") today announced that the article reporting the results of its initial pivotal clinical trial of Ampion(TM) for the treatment of pain due to Osteoarthritis of the knee (OAK), was published in PLOS ONE, an international, rigorously peer-reviewed, open-access, online publication which covers primary research from any discipline within science and medicine, and is...

2014-01-15 08:28:06

Expected to create approximately 40 new jobs over next two years GREENWOOD VILLAGE, Colo., Jan. 15, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) held a groundbreaking ceremony on Friday, January 10th to announce the start of construction of its new state-of-the-art manufacturing facility for its lead drug candidate, Ampion(TM), for the treatment of patients afflicted with osteoarthritis of the knee. Located in the Denver Metro area, the facility is expected to be...

2014-01-13 08:27:33

GREENWOOD VILLAGE, Colo., Jan.13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 500 patient Phase III pivotal trial of Ampion(TM) for the treatment for osteoarthritis of-the-knee (OAK) has received IRB approval and FDA IND clearance and that patients enrollment and treatments have commenced. http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1 (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift,...

2014-01-09 08:27:38

ISO certifications position Luoxis for regulatory clearance and commercialization of the RedoxSYS(TM) diagnostic system. GREENWOOD VILLAGE, Colo., Jan. 9, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has received ISO 13485:2003 certification, an internationally recognized quality standard for medical devices and diagnostics. The company has also earned ISO 9001:2008 certification, a broadly established international quality...

2014-01-06 08:26:22

Research collaborations advance company goal of incorporating RedoxSYS(TM) oxidation-reduction potential platform into clinical practice and broaden the scope of applications in the critical care setting GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece)....


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related